- Home
- OPHC vs NSRX Comparison
OPHC vs NSRX Comparison
Compare OPHC & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPHC | NSRX |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.3M | 52.5M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | OPHC | NSRX |
|---|---|---|
| Price | $5.24 | $5.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.50 |
| AVG Volume (30 Days) | ★ 37.8K | 4.8K |
| Earning Date | 02-02-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | ★ $47,271,000.00 | N/A |
| Revenue This Year | $17,115.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.17 | ★ N/A |
| Revenue Growth | ★ 27.45 | N/A |
| 52 Week Low | $3.53 | $4.90 |
| 52 Week High | $5.17 | $9.99 |
Technical Indicators
Market Signals| Indicator | OPHC | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 77.52 | 41.46 |
| Support Level | $4.70 | $4.90 |
| Resistance Level | $5.17 | $6.30 |
| Average True Range (ATR) | 0.10 | 0.41 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 96.30 | 40.49 |
Price Performance
Historical ComparisonAbout OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, money market deposit accounts, debit cards, and automated teller machines.
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.